Stryker PE Ratio 2006-2018 | SYK
Current and historical PE ratio for Stryker (SYK) from 2006 to 2018. The price to earnings or PE ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. The current PE ratio for Stryker (SYK) as of March 31, 2018 is 25.84.
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $0.003B | $12.444B |
| Stryker Corporation is one of the world's leading medical technology companies and together with its customers, is driven to make healthcare better. The company offers innovative products and services in Orthopaedics, Medical and Surgical, and Neurotechnology and Spine that help improve patient and hospital outcomes. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medtronic (MDT) | Ireland | $119.518B | 18.50 |
| Abbott Laboratories (ABT) | United States | $111.818B | 23.45 |
| Boston Scientific (BSX) | United States | $46.527B | 25.94 |
| Baxter (BAX) | United States | $40.022B | 28.64 |
| Zimmer Biomet Holdings (ZBH) | United States | $22.815B | 14.37 |
| ResMed (RMD) | United States | $15.531B | 32.48 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $15.356B | 0.00 |
| Perrigo (PRGO) | Ireland | $10.500B | 14.72 |
| Bio-Rad Laboratories (BIO) | United States | $9.132B | 73.65 |
| Hill-Rom Holdings (HRC) | United States | $6.219B | 22.34 |
| ICU Medical (ICUI) | United States | $6.169B | 57.40 |
| Canopy Growth (CGC) | Canada | $5.511B | 0.00 |
| Agios Pharmaceuticals (AGIO) | United States | $5.252B | 0.00 |
| Insulet (PODD) | United States | $5.222B | 0.00 |
| Haemonetics (HAE) | United States | $5.160B | 53.14 |
| Hutchison China MediTech (HCM) | China | $4.366B | 0.00 |
| Neogen (NEOG) | United States | $4.219B | 67.46 |
| GW Pharmaceuticals (GWPH) | United Kingdom | $4.127B | 0.00 |
| National Vision Holdings (EYE) | United States | $3.044B | 0.00 |
| NuVasive (NUVA) | United States | $2.767B | 27.97 |
| Quidel (QDEL) | United States | $2.615B | 114.44 |
| Abaxis,Inc (ABAX) | United States | $1.905B | 64.07 |
| Phibro Animal Health (PAHC) | United States | $1.899B | 28.20 |
| NxStage Medical (NXTM) | United States | $1.821B | 0.00 |
| VAREX IMAGING (VREX) | United States | $1.447B | 22.29 |
| Eagle Pharmaceuticals (EGRX) | United States | $1.244B | 34.80 |
| Cardiovascular Systems (CSII) | United States | $1.184B | 0.00 |
| Orthofix (OFIX) | $1.110B | 33.82 | |
| Owens & Minor (OMI) | United States | $1.080B | 10.86 |
| OraSure Technologies (OSUR) | United States | $1.033B | 62.63 |
| AtriCure (ATRC) | United States | $1.027B | 0.00 |
| Cerus (CERS) | United States | $0.973B | 0.00 |
| Omeros (OMER) | United States | $0.968B | 0.00 |
| TG Therapeutics (TGTX) | United States | $0.952B | 0.00 |
| MacroGenics (MGNX) | United States | $0.938B | 0.00 |
| Surmodics (SRDX) | United States | $0.799B | 136.93 |
| LeMaitre Vascular (LMAT) | United States | $0.713B | 41.96 |
| Meridian Bioscience (VIVO) | United States | $0.671B | 23.66 |
| PetIQ (PETQ) | United States | $0.647B | 0.00 |
| Insys Therapeutics (INSY) | United States | $0.612B | 0.00 |
| Lantheus Holdings (LNTH) | United States | $0.530B | 13.85 |
| Evolus (EOLS) | United States | $0.467B | 0.00 |
| Surface Oncology (SURF) | United States | $0.402B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.363B | 24.05 |
| Cytosorbents (CTSO) | United States | $0.360B | 0.00 |
| Quanterix (QTRX) | United States | $0.346B | 0.00 |
| NanoString Technologies (NSTG) | United States | $0.321B | 0.00 |
| BioLife Solutions (BLFS) | United States | $0.299B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.235B | 0.00 |
| Chimerix (CMRX) | United States | $0.220B | 0.00 |
| Bovie Medical (BVX) | United States | $0.171B | 0.00 |
| Fonar (FONR) | United States | $0.169B | 10.23 |
| Chembio Diagnostics (CEMI) | United States | $0.157B | 0.00 |
| Conatus Pharmaceuticals (CNAT) | United States | $0.130B | 0.00 |
| Female Health (VERU) | United States | $0.110B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.104B | 31.00 |
| Oramed Pharmaceuticals (ORMP) | Israel | $0.095B | 0.00 |
| United-Guardian (UG) | United States | $0.088B | 20.48 |
| Neurotrope (NTRP) | United States | $0.081B | 0.00 |
| InfuSystems Holdings (INFU) | United States | $0.075B | 0.00 |
| CAS Medical Systems (CASM) | United States | $0.055B | 0.00 |
| Imprimis Pharmaceuticals (IMMY) | United States | $0.049B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.039B | 0.00 |
| ImmuCell (ICCC) | United States | $0.038B | 0.00 |
| Valeritas Holdings (VLRX) | United States | $0.036B | 0.00 |
| Akers Biosciences Inc (AKER) | United States | $0.035B | 0.00 |
| Myomo (MYO) | United States | $0.033B | 0.00 |
| Senestech (SNES) | United States | $0.026B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.011B | 0.00 |
| NeuroMetrix (NURO) | United States | $0.009B | 0.00 |
| InVivo Therapeutics Holdings (NVIV) | United States | $0.003B | 0.00 |
